NCT01387022View on ClinicalTrials.gov

Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression

NACompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Antiretroviral Treatment Outcomes
Interventions
DRUG

Tenofovir, lamivudine and efavirenz

Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong

Trial Locations (1)

4000

CAPRISA, Durban

All Listed Sponsors
lead

Centre for the AIDS Programme of Research in South Africa

NETWORK

NCT01387022 - Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression | Biotech Hunter | Biotech Hunter